(MENAFN- GlobeNewsWire - Nasdaq) ALLENDALE, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Acuitive Technologies^® commercializes CitregraftTM, with its first use in a surgical case, performed on November 4^th, 2025.

Bone graft substitutes are used to repair defects from trauma, infection, tumor removal, and reconstructive surgery. However, poor handling, low biological activity, variable resorption rate, and inadequate integration limit their effectiveness.

Leveraging the benefits of citrate in bone anatomy and physiology, Acuitive Technologies developed Citregen ^®, a citrate-based polymer technology that mimics natural bone chemistry and supplies the energy needed for regeneration. Exclusively made with Citregen and bioactive glass, Citregraft is a highly porous and bioactive synthetic bone graft substitute designed to interact with proteins to regenerate bony voids within the skeletal system.

Citregraft benefits include:

• Bioactive formulation to improve graft integration
• Easily morselized to fill and hold its position within irregular defects
• Absorbs 5 times its weight in fluids
• Synergizes with bone marrow aspirate (BMA) to bind proteins
• Citrate increases cell energy for tissue regeneration
  

“ Citregraft was easily morselized to fill my tibial harvest site during BPTB ACL reconstruction. After soaking it in saline, it readily absorbed blood and growth factors from the harvest site and conformed perfectly to the defect,” said Robin Gehrmann, MD.

Citregraft overcomes the limitations of conventional bone graft substitutes by improving handling, liquid uptake, and protein binding. Its demonstrated bioactivity and ability to bind proteins establish Citregraft as a viable option for surgeons seeking innovative solutions for bone repair and regeneration.

Media Contact
Thomas McCarthy
Acuitive Technologies, Inc.
...

Data on file, TM251008, at Acuitive Technologies Inc., Allendale, NJ, USA

A photo accompanying this announcement is available at

MENAFN20112025004107003653ID1110372982